prespecified

IZERVAY My WaySM is a patient support program customized to your unique patient-access needs.

Benefits
Investigations

Affordability
Options

Prior Authorization
Support

Patient Assistance
Program

Appeals/Denials
Support

Product
Replacement*

Get started today. Complete IZERVAY My WaySM enrollment in any of the following ways:

Enroll on the IZERVAY My Way Portal

The IZERVAY My WaySM portal is your place for all access and affordability solutions for your patients prescribed IZERVAY™.
Click here to enroll on the portal and complete your registration in just 3 easy steps.

OR

Download the enrollment form and submit it via email or fax
Enrollment Form
Download Enrollment Form
Fax
1-833-C5MYWAY (1-833-256-9929)

If you need assistance, please don’t hesitate to contact our team for live support. Phone: 1-888-C5MYWAY (1-888-256-9929) 8 AM to 8 PM ET Monday – Friday

Once your patient is enrolled, a dedicated Access Coordinator will reach out to you to help your patient get started.

Our broad distribution network is designed to accelerate access.

Authorized specialty distributor
Product order number
Contact information
Website
Besse Medical
10282423
Phone: 800-543-2111
Fax: 800-543-8695
CuraScript Specialty Distribution
478067
Phone: 877-599-7748
Fax: 800-862-6208
McKesson Plasma and Biologics, LLC
2848828
Phone: 877-625-2566
Fax: 888-752-7626
McKesson Specialty Care Distribution
5016156
Phone: 800-482-6700
Fax: 800-800-5673

IZERVAY is also available through a broad open network of specialty pharmacies if mandated by a patient’s health plan. Be sure to contact the specialty pharmacy to confirm availability.

Discover affordability options for your patients across insurance types.

Commercial
Commercial copay program
$0
Eligible commercial patients may pay as little as $0 for their treatment.
Maximum benefit applies. Click here to view complete terms and conditions.

Visit IZERVAYCommercialCopay.com for self-service, copay-only support.

Enroll your patient into our IZERVAY My WaySM program for copay and other offerings with support from an Access Coordinator.

Underinsured/uninsured
Patient assistance program

Financially eligible patients may be able to receive IZERVAY at no cost.

Click here to view terms and conditions.

Enroll your patient into our IZERVAY My WaySM program for copay and other offerings with support from an Access Coordinator.

Download the Billing and Coding Guide for helpful information on coding and billing for IZERVAY

Downloadable Resources

Resources are available for you and your patients throughout their treatment experience.

Distribution and Acquisition Flashcard
Distribution and Acquisition Flashcard
IZERVAY My WaySM Enrollment Form
IZERVAY My WaySM Enrollment Form
Patient Support Program Flashcard
Patient Support Program Flashcard
Commercial copay flashcard
Commercial Copay Flashcard
Sample letter of Medical Necessity
Sample Letter of Medical Necessity
Sample letter of Medical Exception
Sample Letter of Medical Exception
Sample letter of Appeal
Sample Letter of Appeal
FDA Approval Letter
FDA Approval Letter
Billing and Coding Guide
Billing and Coding Guide

Patient Brochure
Patient Brochure
IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
Warnings and Precautions
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure
    • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
Adverse Reactions
  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information or to report an adverse event or product complaint, please call 1-800-707-4479 or send an email to medicalinformation@ivericbio.com.